Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
Search
Close this search box.
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • CIRM Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
Menu
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • CIRM Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

Dr. Mark S Humayun

Return to Grants

Institution Name:
University of Southern California
Total Awards:
5
Award Value:
$44,939,327

Awards as PI

Program Type Institution Grant Title Award Value
Therapeutic Translational Research Projects University of Southern California PRPE-SF, polarized hESC-derived RPE Soluble Factors, as a Therapy for Early Stage Dry Age-related Macular Degeneration $3,697,935
Late Stage Preclinical Projects University of Southern California IND-enabling program for PRPE-SF, the secretome from polarized stem cell-derived RPE cells, for the treatment of dry-age related macular degeneration $5,993,562
Disease Team Planning University of Southern California Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $3,088
Disease Team Therapy Development III University of Southern California Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration $16,339,827
Disease Team Research I University of Southern California Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916
Total:
$44,939,327.14
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us